BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
Rhea-AI Summary
BioHarvest Sciences (NASDAQ: BHST) signed a $1.2 million Stage 2 CDMO contract to develop a rare fragrance raw material using its Botanical Synthesis platform. The deal follows Stage 1 completion in March 2026, when a stable cell bank containing rare molecules was created.
Stage 2, lasting about six to nine months, aims to produce enough material for commercial trials. BioHarvest keeps 20% ownership of successful compositions and is positioned to earn manufacturing revenue and future royalties, targeting production in the second half of 2027.
AI-generated analysis. Not financial advice.
Positive
- $1.2 million Stage 2 CDMO contract for rare fragrance development
- Stage 1 completed with stable cell bank of rare molecule composition
- BioHarvest retains 20% ownership of successfully developed compositions
- Additional manufacturing revenue plus long-term royalty-driven model
- Target readiness for production in second half of 2027
- Access to premium fragrance segment within a $58.9 billion industry
Negative
- Stage 2 timeline of six to nine months before commercial trial material
- Commercial production targeted only in the second half of 2027
- Contract details and plant compounds remain undisclosed under NDA
News Market Reaction – BHST
On the day this news was published, BHST gained 4.07%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $89.54M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BHST was down 7.05% while close peers showed mixed moves: LFVN -2.84%, ABVE -4.35%, DDC -4.11%, HAIN -3.01%, and FTLF up 1.91%. Momentum scanner only flagged LFVN (up), reinforcing a stock-specific setup rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Earnings date notice | Neutral | -0.7% | Scheduled Q1 2026 earnings release and conference call announcement. |
| Apr 29 | Leadership transition | Neutral | -1.2% | Co-founder Dr. Zaki Rakib assumed CEO role to drive CDMO and D2C. |
| Mar 31 | Earnings results | Positive | -0.7% | Reported FY2025 $34.5M revenue, 37% YoY growth, and 2026 guidance. |
| Mar 31 | Fragrance Stage 1 | Positive | +1.6% | Completed Stage 1 stable cell culture for rare fragrance plant with 20% ownership. |
| Mar 26 | VINIA brand milestone | Positive | -0.9% | Announced VINIA as No.1 resveratrol polyphenol brand in the United States. |
Several clearly positive updates (earnings growth, VINIA leadership, Stage 1 fragrance milestone) saw muted or negative next-day moves, with only the initial fragrance Stage 1 news aligning positively.
Over the last few months, BioHarvest reported strong FY2025 growth with revenue of $34.5M (up 37% YoY) and Q4 revenue of $9.1M, alongside 2026 revenue guidance of $42–48M. The company highlighted its CDMO strategy with the initial rare-fragrance Stage 1 milestone on Mar 31, 2026, which drew a 1.64% gain. Separately, VINIA became the No.1 resveratrol polyphenol brand in the U.S. and leadership transitioned to Dr. Zaki Rakib to accelerate the CDMO and D2C “two-lens” strategy. Today’s Stage 2 contract advances that same CDMO fragrance program.
Market Pulse Summary
This announcement advances BioHarvest’s CDMO strategy with a $1.2M Stage 2 contract in a rare, high-value fragrance program, following completion of Stage 1 in March 2026. The company retains 20% ownership of developed compositions and targets production readiness in the second half of 2027. In context of prior updates on FY2025 revenue of $34.5M, VINIA’s U.S. leadership, and the leadership transition to Dr. Zaki Rakib, this news extends the CDMO growth lens into the cited $23B premium fragrance market.
Key Terms
cdmo technical
botanical synthesis technical
cell bank medical
AI-generated analysis. Not financial advice.
Source plant is widely regarded as one of the most valuable fragrance raw materials in the world
Stage 2 contract follows successful Stage 1 completion in March 2026
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 12, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has signed a
This contract is subject to a non-disclosure agreement which prevents the disclosure of the other party and the targeted plant compounds, and follows completion of Stage 1 in March 2026, where a stable cell bank of a unique cell culture-based composition containing rare molecules was produced. At the end of Stage 2, which will take approximately six to nine months, BioHarvest will have produced enough of the fragrance raw material for the purpose of conducting commercial trials.
Under the terms of the Stage 2 agreement with this customer, BioHarvest retains
CEO of BioHarvest Sciences Dr. Zaki Rakib, commented, "A Stage 2 contract means that we have crossed the tallest technological hurdle of this unprecedented research and development journey. It also means we can be ready for production in the second half of 2027, in tandem with an increase in manufacturing capacity due to the planned commissioning of a new production facility. This milestone also brings BioHarvest closer to entering the growing premium fragrance segment, estimated to represent a
The Major Principal of the partner firm, which is a prominent United Arab Emirates-based investment group, commented, "We have gladly awarded BioHarvest this contract after being highly encouraged by the successful completion of Stage 1. Soon, we will be initiating our commercialization program designed to bring the product to market in the second half of 2027."
Dr. Rakib added, "This contract is expected to serve as a catalyst for engaging additional potential customers in other future fragrance programs using BioHarvest's Botanical Synthesis platform. We believe that the unique scalable capability of our technology significantly expands the addressable market opportunity for our CDMO division and strengthens our long-term royalty-driven growth strategy."
Sources:
(1) Grand View Research - Fragrance Market Report (2026-2033)
https://www.grandviewresearch.com/industry-analysis/fragrances-market
About BioHarvest
BioHarvest (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on management's current expectations, beliefs, and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized or will generate royalties to the Company. Successful commercialization of any compound developed will be subject to consumer preferences, advertising budgets and other factors affecting market acceptance of new products which are uncertain and cannot be assured. Launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. There is never an assurance that any product set will successfully disrupt established product categories. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by applicable law. Additional information is contained in the Company's SEC filings, available at http://www.sec.gov.
BioHarvest Company Contact:
Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Chuck Padala, Managing Director
LifeSci Advisors
chuck@lifesciadvisors.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297104